Last reviewed · How we verify

NCT06923124

A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life

Completed Last updated 11 April 2025
What this trial tests

trial in Familial Mediterranean Fever in 44 participants. Completed in 28 May 2024.

Timeline
30 March 2023
Primary endpoint
28 May 2024
28 May 2024

Quick facts

Lead sponsorNovartis Pharmaceuticals
StatusCompleted
Study typeOBSERVATIONAL
Enrollment44
Start date30 March 2023
Primary completion28 May 2024
Estimated completion28 May 2024
Sites1 location across United States

Conditions studied

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Under 28, any sex, with Familial Mediterranean Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was collected retrospectively, from the time of diagnosis to the current moment of the patient's enrollment in the study. Patients had a minimum follow-up of 3 months after diagnosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Familial Mediterranean Fever

Currently open trials in the same condition.

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06923124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing